following a full submission:
ixekizumab (Taltz®) is not recommended for use within NHSScotland.
Indication under review:
Ankylosing spondyloarthritis (radiographic axial spondyloarthritis)
Treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy.
Non-radiographic axial spondyloarthritis
Treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).
In three phase III studies, ixekizumab, compared with placebo, significantly improved symptoms of active radiographic and non-radiographic axial spondyloarthritis (axSpA) in patients who had not previously received biologic medicines, and in patients with active radiographic axSpA who had an inadequate response or intolerance to TNF-alpha inhibitors.
The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Medicine details
- Medicine name:
- ixekizumab (Taltz)
- SMC ID:
- SMC2440
- Indication:
For treatment of adult patients with active radiographic axial spondyloarthritis (rad-axSpA; also known as ankylosing spondylitis [AS] in the literature) who have responded inadequately to conventional therapy and adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).
- Pharmaceutical company
- Eli Lilly and Company Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 13 June 2022